2019
Risk Factors for Kidney Disease in Type 1 Diabetes
Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM, Group O. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019, 42: dc182062. PMID: 30833370, PMCID: PMC6489116, DOI: 10.2337/dc18-2062.Peer-Reviewed Original ResearchConceptsHigher systolic blood pressureHigher mean triglyceridesSystolic blood pressureRisk factorsKidney diseaseBlood pressureIncident macroalbuminuriaMean triglyceridesMultivariable Cox proportional hazards modelsGlomerular filtration rate lossCox proportional hazards modelComplications Trial (DCCT) cohortNonglycemic risk factorsModifiable risk factorsFrequency of screeningAssociation of baselineType 1 diabetesProportional hazards modelGlycemic exposureTrial cohortDiabetes controlMale sexHazards modelClinical strategiesAdvanced stageInternational Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care 2019, 42: 1147-1154. PMID: 30728224, PMCID: PMC6973545, DOI: 10.2337/dc18-2316.Peer-Reviewed Original ResearchConceptsType 1 diabetesSodium-glucose cotransporter inhibitorsDiabetic ketoacidosisCotransporter inhibitorsSGLT inhibitorsNear-normal blood glucose levelsOral antidiabetes medicationsBlood glucose levelsAntidiabetes medicationsInhibitor useBlood pressureAbsolute riskMild hyperglycemiaDKA riskGlycemic variabilityConsensus reportGlucose levelsBody weightDrug AdministrationDiabetesType 1U.S. FoodMedical communityKetoacidosisInternational consensus
2015
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, Saenz AM, Beck RW, Nadeau KJ. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2015, 314: 2241-2250. PMID: 26624824, DOI: 10.1001/jama.2015.16174.Peer-Reviewed Original ResearchConceptsType 1 diabetesBody mass indexGastrointestinal adverse eventsEffect of metforminTotal daily insulinGlycemic controlPlacebo groupOverweight adolescentsMetformin groupBaseline HbA1cAdverse eventsDaily insulinClinical trialsMultiple secondary end pointsOverweight/obese adolescentsSafety of metforminSecondary end pointsUse of metforminAddition of metforminBMI z-scoreMeasures of adipositySecondary outcomesBlood pressureInsulin dosePrimary outcomePresentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study
Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, White NH, Group F. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatric Diabetes 2015, 17: 212-221. PMID: 25690268, PMCID: PMC4539288, DOI: 10.1111/pedi.12264.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetes educationGlycemic controlRecent-onset type 2 diabetesLow-density lipoprotein cholesterolBiochemical parametersCardiometabolic risk factorsDiagnosis of T2DBody mass indexShort-term improvementStandardized diabetes educationInsulin discontinuationTarget HbA1cCommon comorbiditiesInsulin therapyLipoprotein cholesterolMedian hemoglobinBlood pressureMedian ageT2D cohortMass indexTreatment optionsRisk factorsEarly treatmentOutcome measures
2014
Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry
Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, Haller MJ, Network F. Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry. Pediatric Diabetes 2014, 17: 15-20. PMID: 25330905, DOI: 10.1111/pedi.12231.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryElevated blood pressureBlood pressureClinic registryACE-I therapyReceptor blocker therapyGoal blood pressureDiagnosis of hypertensionPediatric diabetes clinicBlocker therapyBP goalHypertensive childrenUndertreated hypertensionARB therapyAggressive managementCardiovascular riskDiabetes clinicHigher BMIMedical recordsHypertensionReceptor inhibitorsDiabetesTherapyVisits
2013
Factors Associated With Microalbuminuria in 7,549 Children and Adolescents With Type 1 Diabetes in the T1D Exchange Clinic Registry
Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, Laffel LM, Miller KM, Speer H, Tamborlane WV, Tansey MJ, . Factors Associated With Microalbuminuria in 7,549 Children and Adolescents With Type 1 Diabetes in the T1D Exchange Clinic Registry. Diabetes Care 2013, 36: 2639-2645. PMID: 23610082, PMCID: PMC3747908, DOI: 10.2337/dc12-2192.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic RegistryAngiotensin receptor blockersType 1 diabetesMA diagnosisDiabetes durationBlood pressureACE inhibitorsClinic registryACEI/ARB treatmentHigher diastolic blood pressureOlder ageRisk of nephropathyLonger diabetes durationDiastolic blood pressureYears of ageBP controlGood glycemicARB treatmentReceptor blockersCreatinine ratioNonmodifiable factorsUrinary albuminHemoglobin levelsFemale sexCurrent treatmentMost Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines
Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE, . Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines. Diabetes Care 2013, 36: 2035-2037. PMID: 23340893, PMCID: PMC3687259, DOI: 10.2337/dc12-1959.Peer-Reviewed Original ResearchConceptsType 1 diabetesT1D Exchange Clinic RegistryBlood pressureClinic registryAmerican Diabetes Association goalsAmerican Diabetes AssociationT1D Exchange RegistryHbA1c targetDiabetes AssociationClinical guidelinesBMI goalPediatric endocrinologistsDiabetesProportion of youthMost childrenRegistryMajority of youthAssociation goalsTwo-thirdsInternational SocietyMost youthTarget levelYearsParticipantsBMI
2010
Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline
Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S. Characteristics of Adolescents and Youth with Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline. The Journal Of Clinical Endocrinology & Metabolism 2010, 96: 159-167. PMID: 20962021, PMCID: PMC3038479, DOI: 10.1210/jc.2010-1642.Peer-Reviewed Original ResearchConceptsType 2 diabetesBlood pressureFamily historyBiochemical abnormalitiesRecent-onset type 2 diabetesLow high-density lipoprotein levelsRecent-Onset Type 2Body mass index z-scoreHigh-density lipoprotein levelsDiabetes care clinicMean diabetes durationYr of diagnosisTODAY cohortBody mass indexIndex z-scoreNon-Hispanic blacksLow socioeconomic statusBaseline data collectionParents/guardiansDiabetes durationBaseline characteristicsHigh triglyceridesCare clinicsLipoprotein levelsMass index
2005
Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors
Burgert TS, Dziura J, Yeckel C, Taksali SE, Weiss R, Tamborlane W, Caprio S. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. International Journal Of Obesity 2005, 30: 273-280. PMID: 16231019, DOI: 10.1038/sj.ijo.0803136.Peer-Reviewed Original ResearchConceptsUrine albumin-creatinine ratioPresence of microalbuminuriaBody mass indexCV riskBlood pressureMetabolic syndromeRisk factorsIndividual CV risk factorsRelationship of microalbuminuriaAlbumin-creatinine ratioCardiovascular risk factorsCV risk factorsOral glucose toleranceInsulin sensitivity indexRisk factor constellationsEarly vasculopathyMicroalbuminuric rangeCardiovascular eventsCV diseaseGross proteinuriaInflammatory markersEndothelial dysfunctionNondiabetic adultsObesity clinicCreatinine ratio
2004
Obesity and the Metabolic Syndrome in Children and Adolescents
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the Metabolic Syndrome in Children and Adolescents. New England Journal Of Medicine 2004, 350: 2362-2374. PMID: 15175438, DOI: 10.1056/nejmoa031049.Peer-Reviewed Original ResearchMeSH KeywordsAdiponectinAdolescentAdultC-Reactive ProteinChildChild, PreschoolFemaleFollow-Up StudiesGlucose Tolerance TestHumansInsulin ResistanceIntercellular Signaling Peptides and ProteinsInterleukin-6Logistic ModelsMaleMetabolic SyndromeObesityPrevalenceProteinsRisk FactorsSeverity of Illness IndexConceptsDegree of obesityC-reactive proteinMetabolic syndromeBody mass indexAdiponectin levelsInsulin resistanceBlood pressureStandard glucose tolerance testC-reactive protein levelsHigh-density lipoprotein cholesterolZ-scoreAdverse cardiovascular outcomesSeverity of obesityGlucose tolerance testLevels of triglyceridesCardiovascular outcomesLipoprotein cholesterolObese subjectsObese childrenUnit of increaseMultiracial cohortNonobese childrenPlasma lipidsChildhood obesityObesity